首页|期刊导航|川北医学院学报|鼠尾草酚通过调控TAK1活性影响慢性阻塞性肺疾病小鼠的炎症反应

鼠尾草酚通过调控TAK1活性影响慢性阻塞性肺疾病小鼠的炎症反应OA

Carnosol influences the inflammatory response in mice suffering from chronic obstructive pulmonary disease through the regulation of TAK1 activity

中文摘要英文摘要

目的:探讨鼠尾草酚对慢性阻塞性肺疾病(COPD)小鼠肺部炎症反应及肺纤维化的影响,验证其是否通过调控TAK1活性发挥作用.方法:将30只雄性C57BL/6小鼠随机分为正常对照组、COPD模型组、鼠尾草酚低剂量组(2.5 mg/kg)、鼠尾草酚高剂量组(5 mg/kg)及地塞米松阳性对照组(1 mg/kg),每组各6只.采用脂多糖(LPS)气管滴注、香烟烟熏联合香烟烟雾提取物(CSE)腹腔注射法构建COPD小鼠模型,建模同时给予相应药物干预,连续7 d.末次给药24 h后,收集血清、支气管肺泡灌洗液(BALF)及肺组织,HE染色观察肺组织病理损伤,Masson染色检测肺组织胶原沉积,ELISA检测血清及BALF中TNF-α、IL-1β水平,Western blot检测肺组织p-TAK1、p-P38、p-P65、p-JNK和IκBα蛋白表达,RT-qPCR检测TAK1 mRNA表达.结果:与正常对照组比较,COPD模型组小鼠肺组织病理损伤严重、炎症细胞大量浸润、胶原纤维显著沉积,肺泡平均截距(MLI)变长(P<0.001),血清及BALF中TNF-α、IL-1β水平升高(P<0.001),肺组织p-TAK1、p-P38、p-P65、p-JNK蛋白及TAK1 mRNA表达水平升高(P<0.001),IκBα蛋白表达水平降低(P<0.001).与模型组比较,低剂量鼠尾草酚可改善肺组织病理损伤,减少炎症细胞浸润,减轻胶原沉积(P<0.05),MLI变短(P<0.05),血清及BALF中TNF-α、IL-1β水平无明显变化(P>0.05),p-TAK1、p-P38蛋白表达水平下降(P<0.01),IκBα蛋白表达水平升高(P<0.01),p-JNK、p-P65蛋白表达水平无统计学差异(P>0.05),TAK1 mRNA表达水平下调(P<0.01);高剂量鼠尾草酚组进一步改善肺组织病理损伤,减少炎症细胞浸润,减轻胶原沉积(P<0.001),MLI进一步变短(P<0.001),血清及BALF中TNF-α、IL-1β水平下降(P<0.05),p-TAK1、p-JNK、p-P38、p-P65蛋白表达水平下降(P<0.01),IκBα蛋白表达水平升高(P<0.001),TAK1的mRNA水平下调(P<0.001).与低剂量鼠尾草酚组相比,高剂量鼠尾草酚组肺部病理损伤更轻,炎症细胞浸润不明显,胶原沉积更少(P<0.01),MLI更短(P<0.05),血清及BALF中TNF-α、IL-1β水平无统计学差异(P>0.05),p-TAK1、p-P38、p-P65蛋白表达水平下降(P<0.05),p-JNK、IκBα蛋白表达水平无统计学差异(P>0.05),TAK1的mRNA水平下调(P<0.001);地塞米松组改善肺组织病理损伤,减少炎症细胞浸润及胶原沉积,降低促炎因子水平,抑制TAK1活性及下游NF-κB/MAPK通路活化的效果与高剂量鼠尾草酚组相当,两组 MLI和TAK1 mRNA水平无统计学差异(P>0.05).结论:鼠尾草酚可通过抑制TAK1的转录水平及磷酸化活性,阻断下游NF-κB/MAPK通路传导,剂量依赖性减轻COPD小鼠肺部炎症反应及肺纤维化,改善肺组织病理损伤.

Objective:To investigate the effects of carnosol on pulmonary inflammation and fibrosis in a murine model of chronic obstructive pulmonary disease(COPD)and to elucidate whether these effects are mediated through the regulation of TAK1 activity.Methods:30 male C57BL/6 mice were randomly allocated into five groups:normal control,COPD model,low-dose carnosol(2.5 mg/kg),high-dose carnosol(5 mg/kg),and dexamethasone positive control(1 mg/kg),with 6 mice in each group.The COPD model was established through intratracheal lipopolysaccharide(LPS)instillation combined with cigarette smoke exposure and intraperitoneal injection of cigarette smoke extract(CSE).Modeling was accompanied by drug intervention,which was administered over a consecutive 7-day period.24 hours following the final administration,serum,bronchoalveolar lavage fluid(BALF),and lung tissues were collected.Hematoxylin-eosin(HE)staining was performed to evaluate pulmonary histopathological changes,while Masson's trichrome staining was utilized to assess collagen deposition.Serum and BALF levels of tumor necrosis factor-α(TNF-α)and interleukin-1β(IL-1β)were quantified by enzyme-linked immunosorbent assay(ELISA).Western blot analysis was conducted to determine the protein expression levels of phosphorylated TAK1(p-TAK1),phosphorylated P38(p-P38),phosphorylated P65(p-P65),phosphorylated c-Jun N-terminal kinase(p-JNK),and inhibitor of NF-κB α(IκBα)in lung tissues.Real-time quantitative polymerase chain reaction(RT-qPCR)was employed to measure TAK1 mRNA expression.Results:Compared with the normal control group,the COPD model group exhibited severe pulmonary histopathological damage characterized by massive inflammatory cell infiltration and substantial collagen fiber deposition,and an increase in mean linear intercept(MLI)(P<0.001).Serum and BALF levels of TNF-α and IL-1β were elevated(P<0.001).Furthermore,the protein expression levels of p-TAK1,p-P38,p-P65,and p-JNK,along with the TAK1 mRNA expression in lung tissues,were upregulated(P<0.001).Meanwhile,the IκBα protein expression was down-regulated(P<0.001).Compared with the model group,low-dose carnosol attenuated histopathological injury in lung tissue,suppressed inflammatory cell infiltration,and mitigated collagen deposition(P<0.05),the MLI was reduced(P<0.05).No significant differences were observed in the concentrations of TNF-α and IL-1β in serum or BALF(P>0.05).At the protein level,p-TAK1 and p-P38 was downregulated(P<0.01),whereas IκBα expression was upregulated(P<0.01).In contrast,no statistically significant changes were detected in the p-JNK or p-P65(P>0.05),the mRNA expression level of TAK1 was down-regulated(P<0.01).In the high-dose carnosol group,histopathological lung injury,inflammatory cell infiltration,and collagen deposition were further attenuated(P<0.001),and MLI was further decreased(P<0.001).TNF-α and IL-1β levels in both serum and BALF were lowered(P<0.05).The levels of p-TAK1,p-JNK,p-P38,and p-P65 were all downregulated(P<0.01),IκBα protein expression was further enhanced(P<0.001),and TAK1 mRNA expression was markedly suppressed(P<0.001).Relative to the low-dose carnosol group,the high-dose group exhibited significantly milder histopathological alterations,less pronounced inflammatory infiltration,and reduced collagen accumulation(P<0.01),along with a shorter MLI(P<0.05).No intergroup differences were observed in serum or BALF TNF-α and IL-1β levels(P>0.05).The levels of p-TAK1,p-P38 and p-P65 were further diminished(P<0.05),there was no difference in the expression levels of p-JNK and total IκBα protein(P>0.05).TAK1 mRNA expression was also lower in the high-dose group(P<0.001).The dexamethasone group demonstrated therapeutic efficacy comparable to that of the high-dose carnosol group across all major endpoints—including attenuation of lung histopathology,suppression of inflammation and fibrosis,reduction of systemic and local pro-inflammatory cytokines,and inhibition of TAK1 activation and downstream NF-κB/MAPK signaling.There was no statistically significant difference in the levels of MLI and TAK1 mRNA between the two groups(P>0.05).Conclusion:Carnosol dose-dependently attenuates pulmonary inflammation and fibrosis in COPD mice by inhibiting TAK1 transcription and phosphorylation,consequently blocking the downstream NF-κB/MAPK signaling cascade and ameliorating pulmonary histopathological damage.

吴玉;欧国春;阿的曲古;李兴玲;蔡竹清;王述红;黄玉芳;邱容

川北医学院临床医学院,四川 南充 637000||遂宁市中心医院全科医学科,四川 遂宁 629000遂宁市中心医院呼吸与危重症医学科,四川 遂宁 629000川北医学院临床医学院,四川 南充 637000西南医科大学附属医院呼吸与危重医学科,四川 泸州 646000遂宁市中心医院全科医学科,四川 遂宁 629000遂宁市中心医院呼吸与危重症医学科,四川 遂宁 629000遂宁市中心医院呼吸与危重症医学科,四川 遂宁 629000遂宁市中心医院呼吸与危重症医学科,四川 遂宁 629000

医药卫生

慢性阻塞性肺疾病鼠尾草酚TAK1NF-κBMAPK

Chronic obstructive pulmonary diseaseCarnosolTAK1NF-κBMAPK

《川北医学院学报》 2026 (8)

908-914,7

国家科技重大专项(2023ZD0506103)

10.3969/j.issn.1005-3697.2026.08.002

评论